Research and


ConfoBody™-enabled drug discovery‚Äč

Confo Therapeutics has the proprietary technology to lock targets in their disease-linked, druggable conformation for hit identification and optimization. This forms the basis of the very sensitive ConfoBody™-enabled screening method (ConfoScreen™), which identifies differentiating chemical series with the appropriate therapeutic mode of action. Such conformation-biased ligands selectively engage only a subset of the receptor's intracellular signaling partners and will deliver superior therapeutic benefit with fewer side effects than current GPCR-targeted drugs.‚Äč

Figure 3: Confo Therapeutics’ proprietary ConfoBody™ platform.